Floatz logo

LEMBOREXANT

Motor Disorder

YangPanSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Motor Disorder cohort.

Asset / SponsorPhaseRating
LEVODOPA
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BBB
TRIMETHOBENZAMIDE
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BB
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-
Novartis Pharmaceuticals
Phase 2BB
APOMORPHINUM
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BB
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4BB

View all 24 →

Same molecule, other indications

LEMBOREXANT is also rated in:

insomniaDormant
BBB
Indicative ·
72 / 100
View asset →
frontotemporal dementiaDormant
BB
Indicative ·
65 / 100
View asset →
dementiaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →